About Drugs in Context

COVID-19: our editorial and production teams are working from home and in safe environments during this difficult time. We will continue to provide peer review and publishing services for authors.

Drugs in Context is an open access, peer-reviewed, continuous publication of international standing. It is a member of the Directory of Open Access Journals (https://doaj.org/). It is listed on PubMed and all articles are free-to-view/download immediately on PubMed Central.

Metrics: SJR/Scimago (2018): SJR = 0.92. Equivalent Impact Factor = 1.087; International collaboration = 39.96%; ranked 96/324 pharmacology journals worldwide by SJR ranking (14/65 open access titles).

Articles: we publish high-quality, peer-reviewed original research papers and topical review articles covering the latest evidence and innovations in drug treatment across all therapeutic areas. Other article types are considered.

Peer review: we conduct single-blind external peer review on all manuscripts with comments from at least two peer reviewers. Our aim is to obtain a first editorial decision within 3 weeks of manuscript submission and online publication within 3 weeks of acceptance.

Submit your manuscript: check the 'SUBMISSION' page for full instructions. Submit your manuscript via Manuscript Manager.

Latest Article

Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs

Alessandro Roggeri BSc, Ferruccio Conte MD, Carlotta Rossi MSc, Mario Cozzolino MD, PhD, Carlo Zocchetti MSc, Daniela Paola Roggeri MSc

Articles 2020

Multifocal infantile haemangiomatosis with hepatic involvement: two cases and treatment management

Antonio Ruggiero MD, Palma Maurizi MD, Silvia Triarico MD, Michele Antonio Capozza MD, Stefano Mastrangelo MD, Giorgio Attinà MD

HIV, drugs and the kidney

Nicola Wearne MBChB, FCP, MMed, Bianca Davidson MBChB, FCP, MMed, Marc Blockman MBChB, BPharm, PG Dip Int Res Ethics, MMed, Annoesjka Swart BScPharm, Erika SW Jones MBBCh, FCP, PhD

Management of psoriasis in pregnancy – a review of the evidence to date

Clara Ferreira MD, Alexandra Azevedo MD, Miguel Nogueira MD, Tiago Torres MD, PhD

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection

Hanh Thi Pham PhD, Meng A Xiao BSc, Miguel AV Principe BSc, Alexander Wong MD, Thibault Mesplède PhD

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms

Benjamin Crooks MA MBBS, Tom Barnes MBBS BSc, Jimmy K Limdi FRCP FACG